Evidence map›Paper›PMID 39957170›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Screening optimal target populations with symptomatic bradyarrhythmia for pharmacotherapy: a discriminant analysis pilot study.

Zhang Wantong, Y I Danhui, L U Fang, Yang Qiaoning, Shi Shuai, L I Qiuyan, Weng Weiliang, Wang Xujie, Zhu Baochen

Abstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhang WantongInstitute of clinical pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Y I DanhuiSchool of Statistics, Renmin University of China, Beijing 100872, China.
L U FangInstitute of clinical pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Yang QiaoningInstitute of clinical pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Shi ShuaiDepartment of General Medicine, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
L I QiuyanNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Weng WeiliangInstitute of clinical pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Wang XujieNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Zhu BaochenDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.

Funding

National Medicine Master's Inheritance Studio Construction Project of the State Administration of Traditional Chinese Medicine (Weng Weiliang Academic Succession Studio), and the Fundamental Research Funds for the Central Public Welfare Research Institutes ZZ14-YQ-006National Natural Science Foundation of China 82004352
6 · The paper itself

Abstract

objectiveTo screen the target population with symptomatic bradyarrhythmia for pharmacotherapy.

methodsThis study use database from clinical trial that use Yuanjiang decoction, a traditional Chinese medicinal prescription. Eligible participants were recruited and treated with Yuanjiang decoction (composed of 6 Chinese herbal medicines), 200 mL twice daily. Cross-contingency analysis, logistic regression analysis, interaction analysis, discriminant analysis and 10-fold cross validation methods were used to establish discriminant model.

resultsThis study concluded that the clinical treatment of bradyarrhythmia has a clear effect. Low minimum heart rate, high maximum heart rate are risk factors that affect the efficacy. Patients with only one comorbid disease did not significantly affect the efficacy, but patient with two or more diseases of coronary heart disease, hypertension, paroxysmal atrial fibrillation, premature ventricular contraction and premature atrial contraction at the same time did not have a good effect. Using the discriminant analysis method to establish a efficacy prediction model, y = 0.07 X 1 + 0.16 X 2 - 0.65 X 3 - 1.12 X 4 - 0.71 X 5 - 0.75 X 6 - 0.91 X 7 (X1 = 24 h mean heart rate, X2 = minimum heart rate, X3= coronary heart disease, X4 = paroxysmal atrial fibrillation, X5 = premature ventricular contraction, X6= sinus block, X7 = atrioventricular block).

conclusionOur model based on the clinical features of patients with bradyarrhythmia. Should be useful aid for predicting pharmacotherapy response and could screen the optimal pharmacotherapy target.

Indexed as

BradycardiaDrugs, Chinese HerbalAdultAgedDiscriminant AnalysisFemaleHeart RateHumansMaleMiddle AgedPilot ProjectsDrugs, Chinese Herbalbradycardiadiscriminant analysisdrug therapyhealth services needs and demandmedicine, Chinese traditional

Identifiers

PMID39957170
PMCPMC11764922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.